More on StemCells (STEM): Q2 beats on EPS but comes up short on revenue. Total sales were up 6% Y/Y, on a 14% increase in product sales. Operating expenses -24%, R&D expenses -26%, and SG&A expenses -16%, all of which helped to boost bottom line margins.
More on StemCells (STEM): Q2 beats on EPS but comes up short on revenue. Total sales were up 6%...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs